Rozanolixizumab
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Rozanolixizumab
- DrugBank Accession Number
- DB14919
- Background
Rozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Rozanolixizumab
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Rozanolixizumab. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Rozanolixizumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Rozanolixizumab. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Rozanolixizumab. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rozanolixizumab. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Rozanolixizumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozanolixizumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Rozanolixizumab. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Rozanolixizumab. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Rozanolixizumab. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P7186074QC
- CAS number
- 1584645-37-3
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Enrolling by Invitation Treatment Generalized Myasthenia Gravis 2 3 Enrolling by Invitation Treatment Primary Immune Thrombocytopenia 1 3 Recruiting Treatment Generalized Myasthenia Gravis 1 3 Recruiting Treatment Primary Immune Thrombocytopenia 2 2 Completed Treatment Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 1 2 Completed Treatment Myasthenia Gravis 1 2 Enrolling by Invitation Treatment Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 1 1 Completed Basic Science Healthy-volunteers 1 1 Not Yet Recruiting Basic Science Healthy Study Participants 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on May 20, 2019 14:35 / Updated on February 21, 2021 18:55